https://mitotics.com/blog Clinical insights on biomarker testing, molecular oncology, precision medicine, immunotherapy, and integrative health from PhD-level scientists. en-us Tue, 26 May 2026 17:45:38 GMT Thu, 28 May 2026 00:00:00 GMT https://mitotics.com/blog/ctdna-mrd-testing-after-cancer-treatment https://mitotics.com/blog/ctdna-mrd-testing-after-cancer-treatment Thu, 28 May 2026 00:00:00 GMT Circulating tumor DNA (ctDNA) and minimal residual disease (MRD) assays can detect recurrence 6–12 months before imaging in many cancer types — but only if you know to ask for them. Here's how the tests work, who they're appropriate for, and how to read the results. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/what-is-an-oncology-consultant https://mitotics.com/blog/what-is-an-oncology-consultant Sat, 23 May 2026 00:00:00 GMT An oncology consultant is an independent specialist who reviews your cancer case alongside your treating team — translating biomarker reports, surfacing clinical trials, and stress-testing the treatment plan. Here's what an oncology consultant actually does, when families hire one, and what it costs. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/braf-v600e-mutation-treatment https://mitotics.com/blog/braf-v600e-mutation-treatment Fri, 22 May 2026 00:00:00 GMT The BRAF V600E mutation is one of the most clinically actionable biomarkers in modern oncology — driving treatment decisions in melanoma, colorectal cancer, thyroid cancer, NSCLC, and a growing list of tissue-agnostic indications. Here's what BRAF V600E means, how it's tested, and the targeted therapies that change outcomes when it's found. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/pharmacogenomics-tamoxifen-aromatase-inhibitors https://mitotics.com/blog/pharmacogenomics-tamoxifen-aromatase-inhibitors Mon, 18 May 2026 00:00:00 GMT Five to ten years of endocrine therapy is standard for hormone receptor–positive breast cancer survivors. Whether you metabolize tamoxifen efficiently — or whether a common antidepressant is silently blocking it — can change the outcome. Here's what to ask for. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/what-is-braf-mutation https://mitotics.com/blog/what-is-braf-mutation Fri, 15 May 2026 00:00:00 GMT If your biomarker report mentions a BRAF mutation, here's what that actually means in plain English — what BRAF does in normal cells, how a mutation changes the picture, which cancers it shows up in, and the questions worth asking your oncology team. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/pik3ca-mutation-breast-cancer https://mitotics.com/blog/pik3ca-mutation-breast-cancer Fri, 08 May 2026 00:00:00 GMT PIK3CA is the single most commonly mutated gene in HR-positive, HER2-negative breast cancer — and it's now a direct treatment target. Here's what a PIK3CA mutation means, how it's tested, when to use alpelisib or capivasertib, and how to plan around toxicity and resistance. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/tme-protocols-tumor-microenvironment-cancer-care https://mitotics.com/blog/tme-protocols-tumor-microenvironment-cancer-care Mon, 04 May 2026 00:00:00 GMT Tumor microenvironment (TME) protocols are emerging as one of the most important shifts in modern oncology — moving beyond the cancer cell itself to target the immune cells, stromal architecture, vasculature, and metabolic conditions that allow tumors to grow and resist therapy. Here's what TME-directed care looks like in 2026, and how a tumor-specific TME report can guide personalized strategy. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/alpelisib-piqray-deep-dive https://mitotics.com/blog/alpelisib-piqray-deep-dive Fri, 01 May 2026 00:00:00 GMT Alpelisib (Piqray®) was the first PI3K inhibitor approved for PIK3CA-mutated, HR+/HER2− advanced breast cancer. Here's a practical, evidence-based deep dive into how it works, who it helps most, real-world dosing, and how to manage the hyperglycemia and rash that drive most discontinuations. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/aacr-2026-san-diego-highlights https://mitotics.com/blog/aacr-2026-san-diego-highlights Sat, 25 Apr 2026 00:00:00 GMT The 2026 American Association for Cancer Research Annual Meeting in San Diego (April 17–22) showcased a generational shift in precision oncology — next-generation KRAS inhibitors targeting G12C and G12D, novel antibody-drug conjugates, ultrasensitive ctDNA monitoring, and AI-driven pathomics. Here's what clinicians and patients should know. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/msi-high-cancer-immunotherapy https://mitotics.com/blog/msi-high-cancer-immunotherapy Fri, 24 Apr 2026 00:00:00 GMT Microsatellite instability–high (MSI-H) is one of the most important biomarkers in modern oncology — it identifies tumors with broken DNA mismatch repair that often respond dramatically to immune checkpoint inhibitors like pembrolizumab. Here's a clear, evidence-based guide to what MSI-H means, how it's tested, and how it changes treatment across cancer types. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/msi-vs-mmr-testing https://mitotics.com/blog/msi-vs-mmr-testing Fri, 17 Apr 2026 00:00:00 GMT MSI and MMR show up on the same pathology reports and often confuse patients and clinicians alike. They measure the same underlying biology with different tools — and knowing the difference helps you read your report, ask better questions, and make sure no treatment option is missed. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/survivorship-care-plans-whats-missing https://mitotics.com/blog/survivorship-care-plans-whats-missing Tue, 14 Apr 2026 00:00:00 GMT Most cancer centers hand out a one-page survivorship care plan at treatment completion. Most of those plans are never used. Here's what a real survivorship plan should include — and the gaps survivors most often need to fill themselves. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/alk-positive-lung-cancer https://mitotics.com/blog/alk-positive-lung-cancer Fri, 10 Apr 2026 00:00:00 GMT ALK-positive non-small cell lung cancer accounts for roughly 5% of NSCLC and is one of the clearest examples of how a single biomarker can transform outcomes. With modern ALK inhibitors, median survival now stretches past 7 years for many patients. Here's a clear guide to testing, first-line drug choice, sequencing on progression, and brain disease. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/alk-rearrangement-explained https://mitotics.com/blog/alk-rearrangement-explained Fri, 03 Apr 2026 00:00:00 GMT An ALK rearrangement is a small chromosomal rewiring that creates an always-on growth signal — and one of the most treatable subtypes of lung cancer. Here's a plain-language explanation of what an ALK rearrangement is, how it's detected, and why it matters for your treatment options. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/how-to-read-comprehensive-metabolic-panel https://mitotics.com/blog/how-to-read-comprehensive-metabolic-panel Tue, 31 Mar 2026 00:00:00 GMT A comprehensive metabolic panel is one of the most commonly ordered blood tests — yet most patients never learn what the 14 markers actually mean. This evidence-based guide decodes every value on your CMP, explains what abnormal results may signal, and shows you when to push for deeper investigation. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/radiation-therapy-limitations-brachytherapy https://mitotics.com/blog/radiation-therapy-limitations-brachytherapy Sun, 29 Mar 2026 00:00:00 GMT External beam radiation remains a cornerstone of cancer treatment, but its indiscriminate approach carries serious consequences. From collateral tissue destruction to increased recurrence risk, here's what patients need to understand — and how targeted alternatives like brachytherapy are changing the conversation. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/mgmt-methylation-glioblastoma https://mitotics.com/blog/mgmt-methylation-glioblastoma Fri, 27 Mar 2026 00:00:00 GMT MGMT promoter methylation is the single most important molecular biomarker in glioblastoma — it predicts whether temozolomide will meaningfully extend life and increasingly guides whether to use chemotherapy at all in older patients. Here's a clear, evidence-based guide for patients and families. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/vitamin-d3-k2-supplementation-evidence https://mitotics.com/blog/vitamin-d3-k2-supplementation-evidence Mon, 23 Mar 2026 00:00:00 GMT A comprehensive, evidence-based review of vitamin D3 and K2 synergy — spanning calcium metabolism, cardiovascular protection, immune modulation, and emerging data on cancer prevention — with clinical dosing guidelines and peer-reviewed citations. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/mgmt-promoter-methylation-test https://mitotics.com/blog/mgmt-promoter-methylation-test Fri, 20 Mar 2026 00:00:00 GMT The MGMT promoter methylation test is one of the most important molecular tests ordered for glioblastoma. Here's a plain-language guide to what's measured, how the lab does it, what the result means, and how to make sure your test was done right. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/braf-mutation-colon-cancer https://mitotics.com/blog/braf-mutation-colon-cancer Fri, 13 Mar 2026 00:00:00 GMT BRAF mutations — most commonly V600E — are found in roughly 10% of metastatic colorectal cancers and define a distinct, more aggressive subtype. The good news: a chemo-free targeted regimen (encorafenib + cetuximab) has become the standard second-line option, and first-line strategies are evolving fast. Here's a clear, evidence-based guide. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/lifestyle-factors-cancer-recurrence-risk https://mitotics.com/blog/lifestyle-factors-cancer-recurrence-risk Fri, 06 Mar 2026 00:00:00 GMT Survivorship marketing is full of supplements and protocols with weak evidence. Here are the lifestyle factors that actually have rigorous studies behind them for lowering cancer recurrence — and the ones that don't, despite the noise. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/er-positive-breast-cancer-tamoxifen-vs-aromatase-inhibitors https://mitotics.com/blog/er-positive-breast-cancer-tamoxifen-vs-aromatase-inhibitors Mon, 02 Mar 2026 00:00:00 GMT A clinical and molecular breakdown of the two primary endocrine therapy strategies for hormone receptor-positive breast cancer — mechanism, patient selection, side effects, and monitoring. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/when-to-push-for-more-than-routine-cancer-surveillance https://mitotics.com/blog/when-to-push-for-more-than-routine-cancer-surveillance Wed, 25 Feb 2026 00:00:00 GMT Standard post-treatment surveillance is built for the average patient. If your situation isn't average — high-risk biology, family history, prior incomplete workup, or evolving symptoms — routine follow-up may not be enough. Here's when to push and what to ask for. kim@mitotics.com (Dr. Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/chronic-lymphocytic-leukemia-2026 https://mitotics.com/blog/chronic-lymphocytic-leukemia-2026 Wed, 18 Feb 2026 00:00:00 GMT MITOTICS® White Paper — Precision Targeting and the latest advances in CLL treatment strategies. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/live-blood-analysis https://mitotics.com/blog/live-blood-analysis Fri, 06 Feb 2026 00:00:00 GMT In the world of integrative and preventative health, understanding what's happening at the cellular level is key. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/mitochondrial-health https://mitotics.com/blog/mitochondrial-health Thu, 29 Jan 2026 00:00:00 GMT Mitochondrial health refers to how well your mitochondria—the tiny energy-producing organelles—are functioning. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/foundationone-biomarker-testing https://mitotics.com/blog/foundationone-biomarker-testing Tue, 27 Jan 2026 00:00:00 GMT Why comprehensive genomic profiling matters — Cancer is not a single disease but hundreds of distinct conditions. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/biomarkers-changing-cancer-care https://mitotics.com/blog/biomarkers-changing-cancer-care Sat, 10 Jan 2026 00:00:00 GMT For decades, cancer treatment was largely guided by where the cancer appeared. Biomarkers are changing that paradigm. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/peptides-pop-culture-science https://mitotics.com/blog/peptides-pop-culture-science Mon, 05 Jan 2026 00:00:00 GMT Peptides have rapidly moved from obscure biochemical compounds to mainstream wellness topics. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/cancer-therapy-breakthroughs-december-2025 https://mitotics.com/blog/cancer-therapy-breakthroughs-december-2025 Wed, 17 Dec 2025 00:00:00 GMT Cancer research continues to move at an extraordinary pace, and this week delivered several major developments influencing clinical decision-making. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/top-medical-breakthroughs-november-2025 https://mitotics.com/blog/top-medical-breakthroughs-november-2025 Fri, 21 Nov 2025 00:00:00 GMT Medical science moves fast — and every week, powerful new discoveries reshape how we diagnose, prevent, and treat disease. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/mrna-influenza-vaccine-breakthrough https://mitotics.com/blog/mrna-influenza-vaccine-breakthrough Mon, 03 Nov 2025 00:00:00 GMT A new mRNA flu vaccine shows superior protection in a Phase 3 trial — what this means for seasonal influenza prevention. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/leading-biomarkers-functional-medicine https://mitotics.com/blog/leading-biomarkers-functional-medicine Sun, 12 Oct 2025 00:00:00 GMT Functional medicine takes a different approach to lab testing — looking upstream at root causes of imbalance using advanced biomarker panels that conventional practice often overlooks. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/biomarker-testing-cancer-diagnosis https://mitotics.com/blog/biomarker-testing-cancer-diagnosis Mon, 06 Oct 2025 00:00:00 GMT Learn which biomarker tests are performed at the onset of a cancer diagnosis and why they matter for personalized treatment. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/skin-virus-role-skin-cancer https://mitotics.com/blog/skin-virus-role-skin-cancer Thu, 02 Oct 2025 00:00:00 GMT New research challenges assumptions about 'harmless' HPV strains and their connection to skin cancer development. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/understanding-thyroid-labs https://mitotics.com/blog/understanding-thyroid-labs Wed, 01 Oct 2025 00:00:00 GMT Your thyroid might be small, but it has a massive impact on your health. Here's what your lab numbers actually mean. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/healthy-blood-pressure-strategies https://mitotics.com/blog/healthy-blood-pressure-strategies Mon, 29 Sep 2025 00:00:00 GMT High blood pressure affects nearly half of U.S. adults. Lifestyle modifications can be equally or more effective than medications. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/colorectal-cancer-rising-young-adults https://mitotics.com/blog/colorectal-cancer-rising-young-adults Sun, 21 Sep 2025 00:00:00 GMT Over the past ~25 years, colorectal cancer incidence has increased substantially in adults under 50. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/digestive-enzymes-probiotics https://mitotics.com/blog/digestive-enzymes-probiotics Fri, 19 Sep 2025 00:00:00 GMT Digestive health is foundational to overall wellness — understanding the role of enzymes and probiotics at the molecular level. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/womens-health-initiative-hormone-therapy https://mitotics.com/blog/womens-health-initiative-hormone-therapy Wed, 17 Sep 2025 00:00:00 GMT If you've ever wondered why hormone therapy has been such a controversial topic, much of the debate traces back to one landmark study. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/hormone-therapy-cholesterol https://mitotics.com/blog/hormone-therapy-cholesterol Wed, 10 Sep 2025 00:00:00 GMT Cholesterol metabolism is tightly regulated — hormone balance is often overlooked as a central regulator of lipid homeostasis. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/molecular-oncology-integrative-cancer-care https://mitotics.com/blog/molecular-oncology-integrative-cancer-care Wed, 03 Sep 2025 00:00:00 GMT Cancer care is evolving. Today, it's no longer enough to treat the tumor alone — the whole patient matters. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/acetaminophen-pregnancy-autism https://mitotics.com/blog/acetaminophen-pregnancy-autism Tue, 26 Aug 2025 00:00:00 GMT A clear, evidence-based summary for clinicians, patients, and advocates on acetaminophen use during pregnancy. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/unlocking-power-of-dna-genetic-services https://mitotics.com/blog/unlocking-power-of-dna-genetic-services Mon, 18 Aug 2025 00:00:00 GMT We provide advanced genetic services designed to help you better understand your unique genetic makeup. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/what-is-crispr-technology https://mitotics.com/blog/what-is-crispr-technology Wed, 06 Aug 2025 00:00:00 GMT CRISPR is a revolutionary gene-editing technology that allows scientists to precisely modify DNA sequences. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/understanding-thyroid-health https://mitotics.com/blog/understanding-thyroid-health Mon, 04 Aug 2025 00:00:00 GMT Thyroid health is important because the thyroid gland plays a central role in regulating metabolism and energy. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/pdl1-inhibitors-cancer-treatment https://mitotics.com/blog/pdl1-inhibitors-cancer-treatment Mon, 04 Aug 2025 00:00:00 GMT PD-L1 inhibitors are a class of immunotherapy drugs that help the immune system recognize and attack cancer cells. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/research-trends-pancreatic-cancer https://mitotics.com/blog/research-trends-pancreatic-cancer Wed, 30 Jul 2025 00:00:00 GMT The latest research in pancreatic cancer is focusing on KRAS-targeted therapies, neoantigen vaccines, and tumor microenvironment modulation. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/hair-tissue-mineral-analysis https://mitotics.com/blog/hair-tissue-mineral-analysis Mon, 28 Jul 2025 00:00:00 GMT HTMA is a non-invasive test that measures mineral levels and toxic metal exposure using a small hair sample. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/biohackers-helping-medical-research https://mitotics.com/blog/biohackers-helping-medical-research Tue, 22 Jul 2025 00:00:00 GMT In recent years, biohacking has gone from fringe subculture to mainstream wellness movement. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/biologic-therapy-autoimmune-disease https://mitotics.com/blog/biologic-therapy-autoimmune-disease Tue, 08 Jul 2025 00:00:00 GMT Biologic therapy represents a major advancement in treating autoimmune diseases by targeting specific immune pathways. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/functional-lab-ranges-matter https://mitotics.com/blog/functional-lab-ranges-matter Tue, 01 Jul 2025 00:00:00 GMT Why functional lab ranges matter more than you think — one of the most important concepts in functional medicine. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/newborn-vitamin-k-injection https://mitotics.com/blog/newborn-vitamin-k-injection Sun, 15 Jun 2025 00:00:00 GMT The vitamin K injection is critical for newborns because it prevents a rare but potentially fatal bleeding disorder. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/pre-statin-workup-panel https://mitotics.com/blog/pre-statin-workup-panel Sun, 11 May 2025 00:00:00 GMT A personalized risk assessment before starting statin therapy — the labs and questions that matter. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/car-t-cell-therapy https://mitotics.com/blog/car-t-cell-therapy Tue, 22 Apr 2025 00:00:00 GMT CAR-T cell therapy is a groundbreaking form of immunotherapy that reprograms a patient's own T-cells to fight cancer. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/biomarker-testing-after-breast-cancer https://mitotics.com/blog/biomarker-testing-after-breast-cancer Sat, 12 Apr 2025 00:00:00 GMT Post-treatment biomarker testing for breast cancer survivors — empowering recovery and supporting long-term health. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/pulmonary-embolism-embolization-therapies https://mitotics.com/blog/pulmonary-embolism-embolization-therapies Sat, 22 Mar 2025 00:00:00 GMT Catheter-directed and mechanical thrombectomy innovations are transforming treatment for pulmonary embolism. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/advancements-chronic-lymphocytic-leukemia https://mitotics.com/blog/advancements-chronic-lymphocytic-leukemia Sat, 08 Mar 2025 00:00:00 GMT Leading-edge clinical advances in CLL including the FLAIR trial, targeted therapies, and MRD-guided approaches. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/tumor-migration-metastasis https://mitotics.com/blog/tumor-migration-metastasis Thu, 13 Feb 2025 00:00:00 GMT Understanding how cancer cells break away from the primary tumor and spread to distant sites in the body. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/tamoxifen-premenopausal-breast-cancer https://mitotics.com/blog/tamoxifen-premenopausal-breast-cancer Tue, 11 Feb 2025 00:00:00 GMT The latest evidence on tamoxifen for premenopausal breast cancer patients, including SOFT/TEXT trial data. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/why-magnesium-vital-nutrient https://mitotics.com/blog/why-magnesium-vital-nutrient Wed, 05 Feb 2025 00:00:00 GMT Magnesium is involved in over 300 enzymatic reactions in the body — why this mineral deserves more attention. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/vitamin-d3-cancer-prevention https://mitotics.com/blog/vitamin-d3-cancer-prevention Tue, 04 Feb 2025 00:00:00 GMT Vitamin D3 plays several important roles in the body that may help prevent cancer development. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/cancer-detection-treatment-advances https://mitotics.com/blog/cancer-detection-treatment-advances Sun, 05 Jan 2025 00:00:00 GMT Advancements in cancer treatment and detection — key developments shaping modern oncology. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/breast-cancer-cases-climbing https://mitotics.com/blog/breast-cancer-cases-climbing Sat, 07 Dec 2024 00:00:00 GMT The rising rates of breast cancer are influenced by a complex interplay of factors — understanding the trends. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/emerging-treatments-autoimmune-diseases https://mitotics.com/blog/emerging-treatments-autoimmune-diseases Wed, 04 Dec 2024 00:00:00 GMT From CAR-T cell therapy to gene editing and inverse vaccines — the frontier of autoimmune disease treatment. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/holistic-doctor-overall-health https://mitotics.com/blog/holistic-doctor-overall-health Fri, 29 Nov 2024 00:00:00 GMT In today's fast-paced, symptom-focused medical world, a holistic approach addresses the whole person. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/cll-treatments-advances-patients https://mitotics.com/blog/cll-treatments-advances-patients Mon, 04 Nov 2024 00:00:00 GMT Chronic lymphocytic leukemia has changed from a disease treated with chemotherapy to one managed with precision therapies. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/what-is-tumor-board https://mitotics.com/blog/what-is-tumor-board Tue, 22 Oct 2024 00:00:00 GMT Get a second opinion — without going anywhere. A tumor board brings multiple specialists together to review your case. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/understanding-tumor-markers https://mitotics.com/blog/understanding-tumor-markers Mon, 14 Oct 2024 00:00:00 GMT Tumor markers are substances produced by cancer cells or the body in response to cancer — understanding their role is crucial. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/biomarker-test-breast-cancer https://mitotics.com/blog/biomarker-test-breast-cancer Wed, 25 Sep 2024 00:00:00 GMT Know your risk: breast cancer biomarkers and prevention strategies for proactive health management. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/commonly-ordered-biomarker-tests https://mitotics.com/blog/commonly-ordered-biomarker-tests Thu, 29 Aug 2024 00:00:00 GMT The most commonly ordered biomarker tests vary depending on the clinical context — a comprehensive overview. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/why-hire-cancer-consultant https://mitotics.com/blog/why-hire-cancer-consultant Mon, 01 Jul 2024 00:00:00 GMT Why hire a cancer biologist or molecular oncology specialist to help navigate your cancer journey. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/are-turbo-cancers-real https://mitotics.com/blog/are-turbo-cancers-real Sun, 02 Jun 2024 00:00:00 GMT The term 'turbo cancer' is not recognized medically — examining the claims with scientific rigor. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/can-cancers-spontaneously-disappear https://mitotics.com/blog/can-cancers-spontaneously-disappear Tue, 02 Apr 2024 00:00:00 GMT What medical research shows regarding spontaneous regression — when cancers disappear without treatment. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/checkpoint-inhibitors-revolutionizing-cancer https://mitotics.com/blog/checkpoint-inhibitors-revolutionizing-cancer Sat, 02 Mar 2024 00:00:00 GMT Checkpoint inhibitors are a class of immunotherapy drugs that have transformed cancer treatment across many tumor types. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/breast-cancer-subtypes https://mitotics.com/blog/breast-cancer-subtypes Tue, 10 Oct 2023 00:00:00 GMT Breast cancer is not a single disease — it's a collection of molecularly distinct subtypes with different behaviors and treatments. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/vitamin-k2-with-d3 https://mitotics.com/blog/vitamin-k2-with-d3 Fri, 22 Sep 2023 00:00:00 GMT Taking vitamin K2 along with vitamin D3 is important because they work synergistically to support bone and cardiovascular health. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/what-are-biologics https://mitotics.com/blog/what-are-biologics Tue, 29 Aug 2023 00:00:00 GMT Biologics are a class of advanced medicines made from living organisms — understanding their role in modern medicine. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/mrna-vaccines-what-to-know https://mitotics.com/blog/mrna-vaccines-what-to-know Tue, 29 Aug 2023 00:00:00 GMT The key difference between mRNA vaccines and traditional vaccines — and what the science shows about safety and efficacy. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/what-is-biomarker-specialist https://mitotics.com/blog/what-is-biomarker-specialist Wed, 02 Jul 2014 00:00:00 GMT Hiring a biomarker specialist in functional medicine, oncology, and precision health — what they do and why it matters. kim@mitotics.com (Kim Lockheimer, PhD, DFM) https://mitotics.com/blog/cancer-risk-assessments https://mitotics.com/blog/cancer-risk-assessments Wed, 02 Jul 2014 00:00:00 GMT If you're proactively looking to reduce your cancer risk, a comprehensive risk assessment is your starting point. kim@mitotics.com (Kim Lockheimer, PhD, DFM)